61 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22757 | 1st line / >= 60 years old / Eligible for standard intensive chemotherapy/ De novo or secondary AML is allowed | Dominique Bron | Acute leukemia | EORTC | 1301-LG | Trial closed for recruitment | 10-day decitabine versus conventional chemotherapy (?3+7?) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group | dominique.bron@hubruxelles.be | 3 | 3 | |
| 22634 | - Histopathological diagnosis of amyloidosis - Measurable disease of amyloid light chain amyloidosis as defined by at least ONE of the following: serum M-protein ?0.5 g/dL by protein electrophoresis or serum free light chain ?50 mg/L - One or more organs |
Nathalie Meuleman | Amyloidose | Janssen | ANDROMEDA | Trial closed for recruitment | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 28653 | age >= 18 YO CTCL-PTCL >= 3th line |
Marie Maerevoet | Lymphoma | Astex Pharmaceuticals | ASTX660-01 | Trial closed | Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas | marie.maerevoet@hubruxelles.be | 1/2 | 1 | |
| 22967 | Relapsed or refractory precursor CD22-positive B-cell ALL and who are eligible for HSCT - Have 1 or more of the following risk factors for developing VOD: a. Due to receive Salvage 2 or greater; b. Prior HSCT;c. Age >=55 years |
Sebastian Wittnebel | Acute leukemia | Pfizer | B1931030 | Trial closed | A phase 4, open label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory b cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno occlusive disease | Sebastian.Wittnebel@hubruxelles.be | 4 | 4 | |
| 29415 | - Newly diagnosed patients with myelodysplastic syndromes defined by WHO 2016 criteria that are about to start treatment. - Patients with a known diagnosis of MDS, irrespective of IPSS and irrespective of time of diagnosis that are about to start a new th |
Sebastian Wittnebel | Blood | BE-QUALMS | Trial closed | A Multicenter observational Belgian study assessing the impact of newly started treatment on the QOL in patients suffering from myelodysplastic syndromes | Sebastian.Wittnebel@hubruxelles.be | 4 | 4 | ||
| 26214 | MCL; 70 years or 65 years with co-morbidities that contraindicate autograft; ECOG 2 | Marie Maerevoet | Non-Hodgkin lymphoma | BeiGene | BGB-3111-306 | Trial open for recruitment | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 28641 | - Relapsed cHL (disease progression after PR or CR to the most recent therapy) or refractory cHL (failure to achieve PR or CR to most recent therapy) - Prior therapy targeting PD-1 or PD-L1, anti-PD-L2, or anti CTLA-4 agent = exclusion criteria |
Marie Maerevoet | Multiple | Lysarc | BGB-A317-210/TIRHOL | Trial closed for recruitment | A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (BGB-A317-210/TIRHOL) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22751 | chronic GVHD - already been treated with first-line systemic therapy for at least 1 month - refractoriness or contraindication/intolerance to current therapy | Philippe Lewalle | NA | BHS | BHS-TC11-01 | Trial open for recruitment | A Phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECPTM (Macropharma) for patients with refractory chronic GVHD | philippe.lewalle@hubruxelles.be | 2 | 2 | |
| 29414 | Hematological malignancies confirmed histologically: - AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC count < 10 000 x109/mL); - MDS; - CML in CP or AP; |
Philippe Lewalle | Acute leukemia | BHS | BHS-TC14 | Trial open for recruitment | Allogenic hematopoietic cell transplantation from HLA-matched donor after FLU-Mel-PTCy versus Flu-Mel-ATG reduced intensity conditioning : a phase III randomized study from the Belgian Hematology Society (BHS) | philippe.lewalle@hubruxelles.be | 2 | 2 | |
| 22719 | Breast implants | Marie Maerevoet | Lymphoma | Lymphoma Academic Research Organization | BIA-ALCL | Trial open for recruitment | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | marie.maerevoet@hubruxelles.be | |||
| 28428 | patients that have initiated reimbursed ibrutinib therapy on or after its launch (via the eHealth procedure) or participated in the Medical Need Program for CLL or MCL and switched to reimbursed ibrutinib on or after 1 August 2015 or had started treatment | Dominique Bron | LLC | Janssen-Cilag N.V. | BiRD | Trial closed | A Retrospective and Prospective Observational Study of ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice Belgian ibrutinib Real-world Data (BiRD) | dominique.bron@hubruxelles.be | |||
| 22645 | - Histologically confirmed MM with measurable disease per IMWG guidelines - Had at least 1 prior anti-MM regimen and no more than 3 prior anti-MM regimens |
Nathalie Meuleman | Myeloma | Karyopharm | BOSTON | Trial closed | A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 29426 | 1.Male or female patients ? 18 years of age. 2.Patients with CML-CP within 3 months of diagnosis* 3.Diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL1 in a review of a minimum 20 m |
Adriano Salaroli | LMC | Novartis | CABL001J12301 | Trial open for recruitment | A Phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | adriano.salaroli@hubruxelles.be | 3 | 3 | |
| 29418 | Stage Mayo IIIb | Nathalie Meuleman | Amyloidose | Caelum Biosciences, Inc. | CAEL101-301 | Trial closed for recruitment | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment- Naïve Patients with Mayo Stage IIIb AL Amyloidosis | nathalie.meuleman@hubruxelles.be | 3 | 3 |